Azenta, Inc. - Common Stock (AZTA)

NEW YORK, May 13, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ:AZTA) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ: AZTA) investors concerning the Company’s possible violations of the federal securities laws.

Law Offices of Howard G. Smith announces an investigation on behalf of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ: AZTA) investors concerning the Company’s possible violations of federal securities laws.

Azenta’s first quarter was marked by operational challenges and a more cautious demand environment, which contributed to results well below market expectatio...

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Azenta (AZTA) To Contact Him Directly To Discuss Their Options

The Law Offices of Frank R. Cruz announces an investigation of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ: AZTA) on behalf of investors concerning the Company’s possible violations of federal securities laws.

NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ:AZTA) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.

The law firm of Kirby McInerney LLP is investigating potential claims against Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ:AZTA). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.

Azenta (AZTA) Q2 2026 Earnings Call Transcript

Life sciences company Azenta (NASDAQ:AZTA) will be announcing earnings results this Wednesday before market hours. Here’s what you need to know. Azenta beat ...

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-...

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline...

What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services ind...

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th...

What Happened? A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the hea...

Over the last six months, Azenta’s shares have sunk to $25.86, producing a disappointing 12% loss - a stark contrast to the S&P 500’s 6.6% gain. This was par...

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.

A number of stocks fell in the morning session after the Trump administration's announcement of new global tariffs reignited trade policy uncertainty. The move came swiftly after the Supreme Court ruled the previous week that the president could not use the International Emergency Economic Powers Act (IEEPA) for such duties, a decision that had initially sent markets higher. However, the administration invoked a different authority, the Trade Act of 1974, to impose a 15% global tariff for up to 150 days. The rapid reimposition of trade barriers creates significant uncertainty for companies across multiple sectors that depend on international supply chains and global trade. Investors are now weighing the potential impact of these new duties on corporate earnings and broader economic activity.